Vestis signals revenue growth of 3%-4% in fiscal 2025 amid improved retention and cost savings
Q1 2025 Management View President and CEO Kim Scott highlighted that Q1 2025 revenue was $684 million, consistent with Q4 2024, while adjusted EBITDA reached $81.2 million, a slight sequential ...
Novartis targets 5%+ annual sales growth through 2029 amid robust brand performance
Q4 2024 Management View CEO Vas Narasimhan highlighted Novartis' strong performance in Q4 2024, with sales increasing 16% and ...